Figure 6. V2 linear peptide–binding mAbs inhibit α₄β₇ binding.

(A) V2 linear peptide–binding mAbs were assayed at 10 μg/mL and 1 μg/mL for blocking α₄β₇ binding to AE.92TH023 cyclic V2 peptide. (B) The B.MN cross-reactive mAb DH813 and DH821 were assayed at 0.061 μg, 0.125 μg, and 0.250 μg for blocking α₄β₇ binding to B.MN cyclic V2 peptide. Graphed are the mean and SD of 2 independent experiments.